UCSD- Moores Cancer Center

La Jolla, California 93093

11 studies enrolling now · 101 studies all time

What they study most

AML, AML, Adult, Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult, Adult T-Cell Leukemia/Lymphoma (ATLL), Advanced Cancer, Advanced Prostate Cancer, Advanced Solid Tumors, Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Antimetabolites, Antineoplastic, Bone Metastases, Brain Cancer

Studies at this site

• Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) — Recruiting now
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation — Recruiting now
• Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer — Recruiting now
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression — Recruiting now
• A Phase 1/1b Study of IAM1363 in HER2 Cancers — Recruiting now
• Neoadjuvant Darovasertib in Primary Uveal Melanoma — Recruiting now
• Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation — Recruiting now
• Study of Personalized Cancer Therapy to Determine Response and Toxicity — Recruiting now
• A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs — Recruiting now
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression — Recruiting now
• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia — Recruiting now
• Quantifying Radiation Induced Vaginal Stenosis — Recruiting now
• Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI — Recruiting now
• Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma — Completed
• PALbociclib CoLlaborative Adjuvant Study — Running, not enrolling
• Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation — Stopped early
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation — Running, not enrolling
• sEphB4-HSA in Treating Patients With Kaposi Sarcoma — Completed
• Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC — Stopped early
• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer — Completed
• Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer — Completed
• Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma — Completed
• Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck — Running, not enrolling
• A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer — Completed
• Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI) — Running, not enrolling
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Running, not enrolling
• Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma — Stopped early
• Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients — Running, not enrolling
• Pembrolizumab in Combination With CRT for LA-SCCHN — Completed
• Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease — Completed
• Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. — Completed
• Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer — Completed
• Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer — Completed
• Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer — Completed
• Connect® Myeloid Disease Registry — Stopped early
• A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies — Running, not enrolling
• Assessing Reproductive Outcomes in Young Female Cancer Survivors Through a National Fertility Preservation Registry — Running, not enrolling
• A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer — Completed
• Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance — Running, not enrolling
• Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma — Paused
• Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer — Paused
• A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer — Completed
• Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) — Stopped early
• Survival Prolongation by Rationale Innovative Genomics — Stopped early
• A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy — Completed
• A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) — Status unconfirmed
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) — Completed
• Atezolizumab Immunotherapy in Patients With Advanced NSCLC — Completed
• Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers — Completed
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors — Completed